Apellis Pharmaceuticals Inc (APLS) concluded trading on Wednesday at a closing price of $17.99, with 7.67 million shares of worth about $138.04 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.70% during that period and on May 07, 2025 the price saw a loss of about -5.91%. Currently the company’s common shares owned by public are about 124.50M shares, out of which, 104.61M shares are available for trading.
Stock saw a price change of -6.35% in past 5 days and over the past one month there was a price change of -9.14%. Year-to-date (YTD), APLS shares are showing a performance of -43.62% which decreased to -62.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $16.98 but also hit the highest price of $47.60 during that period. The average intraday trading volume for Apellis Pharmaceuticals Inc shares is 2.18 million. The stock is currently trading -3.61% below its 20-day simple moving average (SMA20), while that difference is down -17.68% for SMA50 and it goes to -39.25% lower than SMA200.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) currently have 124.50M outstanding shares and institutions hold larger chunk of about 98.91% of that.
The stock has a current market capitalization of $2.26B and its 3Y-monthly beta is at 0.73. It has posted earnings per share of -$1.60 in the same period. It has Quick Ratio of 3.81 while making debt-to-equity ratio of 2.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLS, volatility over the week remained 8.03% while standing at 6.80% over the month.
Analysts are in expectations that Apellis Pharmaceuticals Inc (APLS) stock would likely to be making an EPS of -0.26 in the current quarter, while forecast for next quarter EPS is -0.24 and it is -0.08 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.37 which is -0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 2.85% while it is estimated to increase by 84.87% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on April 29, 2025 offering an Overweight rating for the stock and assigned a target price of $44 to it. Coverage by Goldman stated Apellis Pharmaceuticals Inc (APLS) stock as a Neutral in their note to investors on December 17, 2024, suggesting a price target of $36 for the stock. On November 21, 2024, Morgan Stanley Initiated their recommendations, while on October 25, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $25. Stock get an Outperform rating from William Blair on October 16, 2024.
